Researchers at Uppsala University developed 177Lu-AKIR001, a targeted radiopharmaceutical that achieved 40% complete remission in pancreatic cancer mouse models.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
New targeted radiopharmaceutical therapy induces remission in pancreatic cancer model
CD44v6 Protein Treatment target
40% (12 MBq Dose) Complete remissions in mice
<5% At 5 Years Survival rate
10-20% Of Patients Surgery viable
CD44v6 target accuracy
40% complete remissions
<5% survival rate boost